Sign In
Last checked at 
2 Apr 2026 07:00
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION RELATING TO TRELLUS HEALTH PLC AND ITS SECURITIES FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (596/2014/EU) AS IT FORMS PART OF THE DOMESTIC LAW OF THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("EUWA") AND AS MODIFIED BY OR UNDER THE EUWA OR OTHER DOMESTIC LAW, INCLUDING BUT NOT LIMITED TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR").
Trellus Health plc
("Trellus Health" or the "Company")
Funding Update
Trellus Health plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programmes and value-based solutions to manage complex chronic conditions, announces that it has entered into an unsecured loan agreement with the Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder, with a principal amount of US$50,000 (the "Loan Note").
Loan Note Terms
The Loan Note will accrue interest at an annual rate of 5%, payable in cash at maturity of the loan. The loan term is 12 months.
Cash Runway
The proceeds from the Loan Note will extend the Company's cash runway into late April 2026. The Convertible Facility provided by Alumni Capital LLC remains in place, although utilisation continues to be currently constrained by market conditions.
As stated in the announcement of 27 March 2026, the Board remains supportive of the Company's commercial strategy and is engaged in ongoing discussions regarding a range of potential funding options to further extend the Company's cash runway.
Related Party Transaction
The Loan Note is deemed to be a related party transaction under AIM Rule 13 of the AIM Rules for Companies as Dr. Marla Dubinsky is a director of the Company. The Company's Independent Directors consider, having consulted with the Nominated Adviser, Singer Capital Markets, that the terms of the related party transaction are fair and reasonable insofar as the shareholders of the Company are concerned.
Enquiries:
Trellus Health plc | https://trellushealth.com/
| ||||
Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder | Via Walbrook PR | ||||
Joy Bessenger, Chief Financial Officer | |||||
Singer Capital Markets (Nominated Adviser and Broker) | |||||
Philip Davies / Jalini Kalaravy / Samed Ethemi | Tel: +44 (0)20 7496 3000 303/ | ||||
Walbrook PR | Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com | ||||
Lianne Applegarth / | Mob: +44 (0)7584 391 303/ | ||||
Alice Woodings
| +44 (0)7407 804 654
| ||||
About Trellus Health plc (www.trellushealth.com)
Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.
Trellus Health® integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions and therapeutic areas, Trellus Health® considers its approach to have potential utility and demand across many conditions.
The Company also offers Trellus TrialSet™, a solution for pharmaceutical partners spanning clinical trials to commercialisation, applying the same validated resilience science and platform to support trial success and long-term patient engagement
The Company was founded by Icahn School of Medicine at Mount Sinai faculty members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading experts in treating both the physical and emotional impacts of IBD, with a combined 50 years of pioneering whole-person healthcare innovation.
Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: www.trellushealth.com
Follow the stocks
